Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
PenumbraAbbVie
Last price
$317.65$262.96
Currency
USD
USD
$12B$470B
77.9675.08
$4.07$3.54
0.700.28
0$6.83
02.60%
Sector
HealthHealth
Employees
4,70057,000
Ticker
$PEN$ABBV
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $PEN or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.